Combined chemotherapy and allogeneic human Vγ9Vδ2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo

Ovarian cancer statistics, 2018

(2018) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

(2016) Joyce F. Liu et al.   CLINICAL CANCER RESEARCH

Adoptive immunotherapy against ovarian cancer

(2016) Gloria Mittica et al.   Journal of Ovarian Research

Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors

(2016) Ulrich Jarry et al.   OncoImmunology

Molecules and Mechanisms Implicated in the Peculiar Antigenic Activation Process of Human Vγ9Vδ2 T Cells

(2015) Christelle Harly et al.   Frontiers in Immunology

γδT Cells: First Line of Defense and Beyond

(2014) Yueh-hsiu Chien et al.   Annual Review of Immunology

Tumorgrafts asIn VivoSurrogates for Women with Ovarian Cancer

(2014) S. John Weroha et al.   CLINICAL CANCER RESEARCH

First In-Mouse Development and Application of a Surgically Relevant Xenograft Model of Ovarian Carcinoma

(2014) Øystein Helland et al.   PLoS One

Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer

(2013) Pierre-Emmanuel Colombo et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human    T-cell subset

(2012) C. Harly et al.   BLOOD

What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

(2012) Jean-Jacques Fournié et al.   Cellular & Molecular Immunology

Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes

(2011) Dongmei Lai et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: Implications for immunotherapy

(2011) Vincent Lavoué et al.   INTERNATIONAL JOURNAL OF CANCER

Anticancer Properties of Zoledronic Acid

(2010) Jonathan Green et al.   CANCER INVESTIGATION

Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes

(2010) Juan R. Cubillos-Ruiz et al.   CELL CYCLE

Zoledronic Acid

(2008) Sohita Dhillon et al.   DRUGS